In the News


Immunexpress Saving Lives with Improved Sepsis Diagnosis: Interview with Rolland Carlson PhD, CEO

Medgadget editor Tom Peach sat down with Dr.Carlson from Immunexpress to hear more about the company’s first FDA-approved sepsis diagnostic test, SeptiCyte, and what the future of sepsis diagnosis and treatment may look like.  
Health Leaders

3 Need-to-Know Leaps in Sepsis Care

Rolland Carlson, PhD, CEO of Immunexpress, discusses a different approach to the sepsis battle. Rather than passively chasing pathogens, the Company has developed a test to measure the body's specific immune response to infection by examining biomarkers in the patient's blood.

Appointments and advancements – Fayyaz Memon

Immunexpress continues executive team expansion with addition of Fayyaz Memon as VP of Regulatory Affairs & Quality.
genome web

People in the News: Rolland Carlson, Tanja Dowe, Katleen Verleysen

Accomplished industry leaders join recently appointed CEO, Dr. Rolland Carlson, to expand on the comprehensive experience of the Board.

Appointments and advancements – Rolland Carlson, Tanja Dowe, Katleen Verleysen

Immunexpress strengthens Board of Directors with key appointments.
pulmonary advisor

Molecular Laboratory Test Can Discriminate Sepsis From Noninfectious SIRS

Design and results of clinical trials that led to FDA clearance of SeptiCyte™ LAB published in the American Journal of Respiratory and Clinical Care Medicine.

Product Briefs – SeptiCyte LAB

Immunexpress, Inc. published in the American Journal of Respiratory and Clinical Care Medicine the design and results of clinical trials validating SeptiCyte™ LAB in the discrimination of sepsis from non-infectious systemic inflammatory response syndrome (SIRS) in the Intensive Care Unit (ICU) of hospitals.
genome web

Biocartis Partnership May Enable Immunexpress to Move Sepsis Test to Point of Care

Biocartis Group NV (‘Biocartis’), an innovative molecular diagnostics company and Immunexpress have entered into a partnership agreement aimed at the development and commercialization of Immunexpress’ SeptiCypte™ test for use on Biocartis’ sample-to-result Idylla™ platform.

Brief-Biocartis & Immunexpress Partnership For A Sepsis Host Immune Response Test

Immunexpress and Biocartis enter an agreement to develop and commercialize SeptiCyte™ technology for use on sample-to-result Idylla™  platform.
genome web

Biocartis, Immunexpress Partner to Develop Sepsis Test

Biocartis and Immunexpress partner to develop a fully automated sepsis test, allowing for fast near-patient testing, resulting in potentially life-saving clinical information.

Biocartis, Immunexpress Partner to Develop Sepsis Test

Biocartis & Immunexpress sign partnership for a sepsis host immune response test on the Idylla™ platform.
news medical life science.

Differentiating sepsis and systemic inflammatory response syndrome using biomarkers

An interview with Dr. Richard Brandon, Chief Scientific Officer, Immunexpress, conducted by April Cashin-Garbutt, MA (Cantab).